Helix BioPharma Corp.
TSX:HBP.TOBiotechnology
-$0.07 today
- Market cap
- $65.69M
- Beta
- -0.29
- P/E (TTM)
- -32.6
- EPS (TTM)
- -$0.04
Volume 0.00M
Average 0.00M
HBP.TO Total Non-current Assets
All assets not expected to be converted to cash within one year.
Helix BioPharma Corp.TSX: HBP.TO
Total Non-current Assets · Q3 FY2026 · quarter ended Apr 2026
Total non-current assets rises 262614.3% from a year ago
Total non-current assets stood at CA$18.39M at the end of Q3 FY2026, up 262614.3% from a year earlier and up 0.0% from the prior quarter. Over 3 fiscal years it compounded at +707.0% a year.
Context
- Total non-current assets amounted to 86.0% of total assets at the end of Q3 FY2026, up 85.3 pp from a year earlier.
- Total non-current assets increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current assets keeps rising in the next quarterly balance sheet after a +262614.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
- Latest quarterApr 2026
- CA$18.39M+0.0% QoQ
- Last fiscal yearJul 2025
- CA$18.39M+55636.4% YoY
- Year agoApr 2025
- CA$7K+262614.3% since
Total Non-current Assets history
CAD · from the balance sheet
- Latest · FY2025
- 18.39M CAD
- Year-over-year change
- +55636.4%
- 4-year CAGR
- +344.8%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-07-31 | 18.39M | +55636.4% |
| FY2024 | 2024-07-31 | 33K | +0.0% |
| FY2023 | 2023-07-31 | 33K | -5.7% |
| FY2022 | 2022-07-31 | 35K | -25.5% |
| FY2021 | 2021-07-31 | 47K | — |
Total Non-current Assets vs competitors
How HBP.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +262614.3% is the highest of 5, against a peer median of -19.3%.
- Total non-current assets amounts to 86.0% of total assets for HBP.TO, versus a peer median of 0.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $102.21M USD | -14.7% | -18.1% | 77.9% | |
| Apr 2026 | CA$18.39M CAD | +262614.3% | +707.0% | 86.0% | |
| Mar 2026 | CA$138.97K CAD | -23.9% | -41.5% | 0.4% | |
| Apr 2026 | CA$8.86K CAD | -99.1% | -44.3% | 0.6% | |
MSCL.TOSatellos Bioscience Inc. | Mar 2026 | $8.01K USD | +166.8% | -89.2% | 0.0% |
| Peer median (excluding HBP.TO) | — | -19.3% | -42.9% | 0.5% | |
Competitors are the stored peer set for HBP.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Helix BioPharma Corp.
TSX:HBP.TO
Intrinsic Alpha fair value
Locked
Current Price
$0.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.